Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

@article{Armstrong2010ProphylaxisOC,
  title={Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.},
  author={Edward P. Armstrong},
  journal={Journal of managed care pharmacy : JMCP},
  year={2010},
  volume={16 3},
  pages={217-30}
}
BACKGROUND Vaccines have demonstrated cost-effectiveness in managed care through the prevention of disease. As new vaccines for previously untargeted conditions are developed, pharmacoeconomic modeling is becoming even more critical for the quantification of value in the health care industry. Two recently developed vaccines aimed at prevention of infection from human papillomavirus (HPV) types 16 and 18 have proven to be highly efficacious. HPV 16 and 18 are the 2 most common oncogenic strains… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 65 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Factors associated with completion of the human papillomavirus vaccine series

  • BA Slade, L Leidel, C Vellozzi
  • Clin Pediatr ( Phila )
  • 2009

Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant] suspension for intramuscular injection

  • Merck, Co
  • Revised October
  • 2009

Similar Papers

Loading similar papers…